Production Capability Expansion
With an already operating production line in Israel and a production line set up for operation in April 2018 in China, the Company is ready to reach production capabilities of up to one million units in the first year. During its first year of operation, the Chinese office is expected to have four active product lines and local capabilities of manufacturing, Quality Assurance, Quality Control and independent purchasing. Direct Sales
During the past year, G Medical Innovations set up the infrastructure for a direct sales online store for the Prizma monitoring technology and services. Set to launch in March 2018, the online store will allow consumers from all over the world to purchase a Prizma directly and sign up for supporting services provided in their country. Focus on China
As the world’s largest economy with almost 20% of the global population, China faces a significant challenge in providing sufficient healthcare for its people. G Medical Innovations established a Joint Venture with GIBF, a Chinese fund, which has injected 5 million US dollars so far into the company, and will continue to provide up to 10 million dollars with no dilution. This is a major milestone for the company because it is at the core of our business in China. This market is growing fast and G Medical Innovations believes that its solutions are an excellent fit for this market.
GMV Price at posting:
25.0¢ Sentiment: Hold Disclosure: Held
